SBIR/STTR Research Award

Optogenetic control over transgene expression for the therapy of brain and spine

Award identifier 95b7c17a5edbbbe7ac713e56b606e7a81f0b4e82cb2a83e6b3e68ada1d3cc2a2Awarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$220,083

Program and phase

SBIR · Phase I

Award year

2017

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
LOCALIZED THERAPEUTICS LLC
Proposal award date
2017-08-01
Contract end date
2019-03-31
UEI
SAL7W6C1KMJ4
Solicitation number
PA15-269
Topic code
101

Research abstract

Optogenetic control over transgene expression for the therapy of brain and spine Abstract Gene modified stem cells are a powerful tool for the production of secretable therapeutic proteins in the body Yet there is a valid concern over their safety since there is no way to control them once they have been transplanted We propose to utilize optogenetic control of transcription ORT to externally control secretion of the therapeutic protein using red light ORT would improve the efficacy and safety of the therapy by repeated remote activation of transgene synthesis with red light delivered non invasively For a specific disease application we propose to use intrathecally delivered ORT driven stem cells to produce anti inflammatory anti TNF hybrid antibodies in the subarachnoid cavity for the therapy of neuroinflammation in the brain The ORT option would allow us to externally induce production of the anti inflammatory antibody using red light as needed At this initial phase of the project we propose the conceptual evaluation of the ORT system genetically embedded into bone marrow stem cells This testing is proposed in cell culture Aim and the mouse cerebral subarachnoid cavity Aim The proposed method aims to improve the safety and efficiency of the therapy of chronic CNS disorders with episodic neuroinflammatory components by providing the benefit of remote control of the timing and dosage of the therapy Narrative Gene modified stem cells offer promise for the therapy of central nervous disorders However the current methods of delivery and dosage adjustment are not sufficiently safe This proposal offers to test a novel concept of producing a biological drug in the subarachnoid cavity of the brain under repetitive induction by red light In this phase we propose to perform the initial evaluation of this technology in cell culture and a mouse model The option of control over gene modified cell activity would improve the efficacy and safety of central nervous system therapy opening new opportunities for treatment of brain and spinal cord disorders The proposed technology has the potential to facilitate the therapy s dosage adjustment and administration timing thus improving the quality of life and comfort of neuropsychiatric patients

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

2 SBIR/STTR records share this UEI (2015–2017). Reported award amounts total $443,571. Reported amounts are not federal obligations.

Phases: Phase I

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.